

# Purmorphamine as a Shh Signaling Activator Small Molecule Promotes Motor Neuron Differentiation of Mesenchymal Stem Cells Cultured on Nanofibrous PCL Scaffold

Naghmeh Bahrami<sup>1,2,3</sup> · Mohammad Bayat<sup>1,2</sup> · Abdolreza Mohamadnia<sup>4,5</sup> · Mehrdad Khakbiz<sup>6</sup> · Meysam Yazdankhah<sup>7</sup> · Jafar Ai<sup>8</sup> · Somayeh Ebrahimi-Barough<sup>8</sup>

Received: 5 July 2016 / Accepted: 30 August 2016 / Published online: 14 September 2016  
© Springer Science+Business Media New York 2016

**Abstract** There is variety of stem cell sources but problems in ethical issues, contamination, and normal karyotype cause many limitations in obtaining and using these cells. The cells in Wharton's jelly region of umbilical cord are abundant and available stem cells with low immunological incompatibility, which could be considered for cell replacement therapy. Small molecules have been presented as less expensive biologically active compounds that can regulate different developmental process. Purmorphamine (PMA) is a small molecule that, according to some studies, possesses certain differentiation effects. In this study, we investigated the effect of the PMA on

Wharton's jelly mesenchymal stem cell (WJ-MSC) differentiation into motor neuronal lineages instead of sonic hedgehog (Shh) on PCL scaffold. After exposing to induction media for 15 days, the cells were characterized for expression of motor neuron markers including PAX6, NF-H, Islet1, HB9, and choline acetyl transferase (ChAT) by quantitative reverse transcription (PCR) and immunocytochemistry. Our results demonstrated that induced WJ-MSCs with PMA could significantly express motor neuron markers in RNA and protein levels 15 days post induction. These results suggested that WJ-MSCs can differentiate to motor neuron-like cells with PMA on PCL scaffold and might provide a potential source in cell therapy for nervous system.

✉ Somayeh Ebrahimi-Barough  
Ebrahimi\_s@sina.tums.ac.ir

**Keywords** Motor neuron differentiation · Wharton's jelly mesenchymal stem cells · Purmorphamine · PCL scaffold

- <sup>1</sup> Oral and Maxillofacial Surgery Department, School of Dentistry, Tehran University of Medical Sciences, Tehran, Iran
- <sup>2</sup> Craniomaxillofacial Research Center, Tehran University of Medical Sciences, Tehran, Iran
- <sup>3</sup> Iranian Tissue Bank and Research Center, Tehran University of Medical Sciences, Tehran, Iran
- <sup>4</sup> Virology Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
- <sup>5</sup> Department of Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
- <sup>6</sup> Biomedical Engineering Division, Life Science Engineering Department, Faculty of New Sciences and Technologies, University of Tehran, North Karegar Ave, P.O. Box 14395-1561, Tehran, Iran
- <sup>7</sup> Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA
- <sup>8</sup> Department of Tissue Engineering and Applied Cell Sciences, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran

## Introduction

Neuronal cell loss is common feature for large numbers of neurodegenerative diseases such as Parkinson's disease, spinal cord injury, stroke, and Huntington's disease (HD) that are associated with loss of function and disabilities [1–3]. There are many limitations in injured regions in the CNS, and this problem greatly limits effective therapeutic possibilities [4]. Cell replacement therapy for injured regions has provided powerful new therapeutic strategies for human neurological diseases [1, 5]. There are many sources of stem cells that are used for neural differentiation [6, 7]. Embryonic stem cells (ESCs) and adult stem cells have been differentiated into neural cells that are used for repairing of neurodegenerative diseases [8–12]. For clinical application, it is important that these cells have the relative ease of isolating

and expanding process [13]. Conversely, mesenchymal stem cells derived from Wharton's jelly mesenchymal stem cells (WJ-MSCs) within the umbilical cord are easy to be obtained and do not give rise to any ethical issues, not tumorigenic, and preserve their normal karyotype after several passages [14–18]. Previously, the differentiation potential of this source of cells into many types of cells such as osteoblast, adipocyte, and neural cells has been studied [16, 19, 20]. Thus, human umbilical cord mesenchymal stem cells may serve as an alternative source of multipotent stem cells for replacement therapy [16]. It is previously shown that WJ-MSCs can be differentiated to motor neurons by applying retinoic acid (RA) and sonic hedgehog (Shh) [16, 18]. In the present study, we also discovered that motor neuron differentiation from WJ-MSCs can be achieved by using a small molecule, purmorphamine, instead of Shh. Recently, the effect of a small molecule termed 2,6,9-trisubstituted purine or purmorphamine has investigated on osteogenesis and neurogenesis by activation of the hedgehog signaling pathway [21–24]. Upregulation of Gli-1 transcription factor is important for neural differentiation that can be occurred by activation of Shh signaling pathway by purmorphamine [25]. Identification of small molecules that selectively induce neural differentiation from MSCs would provide useful chemical tools to study the molecular mechanisms of neural differentiation and ultimately might lead to useful therapeutic agents for the treatment of neurodegenerative diseases [26].

Tissue engineering is a new potential approach to enhance cell survival and differentiation using materials. A variety of natural and synthetic polymers for nerve tissue engineering have been investigated by variety of studies such as polycaprolactone (PCL), poly(L-lactide-co-glycolide) (PLGA), collagen, and gelatin [16, 27]. PCL has good mechanical properties, biodegradability, and biocompatibility, which has been shown to be suitable for constructing scaffold for differentiation of stem cells to different types of cells such as neural cells [16, 27]. Among different methods for scaffold fabrication, electrospinning has drawn attention because it is an easy, cost-effective technique and provides a proper matrix with high surface area to volume ratio and fiber diameters in the range of nanometer with sufficient pores to encourage mesenchymal stem cell (MSC) adhesion, proliferation, and differentiation [28].

In the present study, we investigated the directed differentiation of human WJ-MSCs cultured on PCL nanofibrous scaffold into motor neuron-like cells in the presence of purmorphamine as an agonist of Shh signaling. PCL nanofibrous scaffold was fabricated by electrospinning technique, and then differentiation of WJ-MSCs into motor neuron cells on PCL scaffold was characterized by investigating their morphology and specific gene expression.

## Material and Methods

### Mesenchymal Stem Cell Isolation from Wharton's Jelly

Human WJ-MSCs were obtained by our previous study protocol [17]. Briefly, the sample of human umbilical cords (hUCs) was collected after filling consent forms by the newborns' parent. Cord was rinsed with PBS to remove blood in excess and was processed within 2–4 h of the births. After that, hUC was cut into 3–5-cm pieces, and cord vessels were removed to avoid endothelial cell contamination. Wharton's jelly parts were digested with collagenase I (1 mg/ml; Sigma-Aldrich, USA) for 3 h at 37 °C and further digested with dispase enzyme at 37 °C for 1 h and then centrifuged at 1500 rpm for 5 min at 4 °C. After discarding the liquid, isolated cells were cultured in Dulbecco's modified Eagle medium/F12 (DMEM/F12; Invitrogen, USA), 10 % fetal bovine serum (Invitrogen USA), 100 U/ml penicillin/streptomycin (Sigma, USA) and plated into a 25-cm<sup>2</sup> flask and maintained at 37 °C in a 5 % CO incubator. Medium was renewed every 3 days, and adherent cells were serially passaged at 80–90 % confluence at 1:3 ratio. WJ-MSCs were characterized using flow cytometry for cell surface markers including CD90, CD105, CD73, CD45, and CD34 [17].

### Fabrication of Electrospun PCL

To obtain nanofibrous scaffolds, PCL polymer (10 % w/v; Mw 80,000 g/mol, Sigma-Aldrich, USA) was dissolved in mixture of dichloromethane (DCM), *N,N*-dimethylformamide (DMF) at the ratio of 1:3 and stirred for 24 h at room temperature. The polymer solution was placed into a 5-ml plastic syringe at room temperature. Applied voltage was 15 kV and the feeding rates were kept constant at 1.3 ml/h. As grounded collector, a piece of aluminum foil was placed toward the tip at the distance of 12 cm.

### Cell Seeding on PCL Scaffolds

WJ-MSCs were cultured in DMEM/F12 (Gibco, USA) supplemented with 10 % FBS. When the confluence of cells reached 85–90 % at passage 3, the cells were used for seeding on scaffolds. The scaffolds were cut to the size of a well from a 24-well plate (16 mm) using a punch. Scaffolds were sterilized by exposing to UV radiation for 1 h and incubated in DMEM/F12 containing 10 % FBS for 2 h before cell seeding. The cells were dropped onto the top of the scaffolds with a final seeding density of  $5 \times 10^4$  cells/cm<sup>2</sup> of scaffold in 24-well plates and incubated for 2 h to allow cells to attach onto the surface of the scaffold. New medium was then added for further incubation.

## Scanning Electron Microscopy

The average of fiber diameter and diameter distribution of the fibers were measured by analyzing of SEM micrographs by using the Image J software from 50 fibers per condition. To SEM of WJ-MSCs cultured on nanofibrous scaffolds for 5 days, cell-containing scaffolds were fixed with 2.5 % glutaraldehyde for 1 h and dehydrated in series of sequentially increasing concentration of ethanol solutions (30, 50, 70, 80, 90, and 100 %) for 10 min per each concentration. Critical point-dried samples were sputter-coated with gold and examined using a scanning electron microscope (model Philips XL-30, Netherland), operated at 15 kV.

## Cell Viability and Proliferation Assay

The 3-(4,5-dimethylthiazoyl-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was used to measure metabolic activity of the WJ-MSCs cultured on the electrospun PCL nanofibrous scaffolds. Cells were seeded at a density of  $5 \times 10^4$  cells/scaffold in 24-well plates and incubated at 37 °C under 5 % CO<sub>2</sub> for 1, 3, 5, and 7 days. For this assay, 400 µl of 5 mg/ml MTT solution was added to each well and incubated at 37 °C for 4 h. The medium was removed, the formazan crystals were dissolved in DMSO, and absorbance at 570 nm was measured using an ELIZA reader (Asys Hitch, Ec Austria).

## Induction of WJ-MSCs into Motor Neuron-Like Cells with purmorphamine

For motor neuron-like cell induction, WJ-MSCs were seeded at 5000 cells/cm<sup>2</sup> on PCL scaffolds as 3D culture and 24-well tissue culture polystyrene (TCP). The cells were incubated with DMEM/F12 medium supplemented with 10 % FBS, 100 U/ml penicillin, and 1 mg/ml streptomycin for 24 h. Differentiation of cells was induced by exposing the cells to preinduction medium composed of DMEM/F12 (1:1), 20 % FBS, 2 % B27, 10 ng/ml fibroblast growth factor 2 (FGF2), 250 µM isobutylmethylxanthin, and 100 µM 2-metcaptoethanol and incubated for 24 h at 37 °C and 5 % CO<sub>2</sub>. The treated cells were then cultured in induction media containing DMEM/F12 (1:1), 0.2 % B27, 1 µM of purmorphamine (PMA), and 0.01 ng/ml retinoic acid (RA) for 1 week. Then, the induced media was replaced with a medium composed of DMEM/F12 (1:1), 0.2 % B27, and 200 ng/ml brain-derived neurotrophic factor (BDNF) for another 1 week. As a control, a group of WJSCs was cultured on the 3D cultures or 2D cultures in the absence of differentiation factors for 15 days. The medium was changed every 3 days.

## Immunofluorescence Analysis

After induction to motor neuron cells, cells were fixed with 4 % paraformaldehyde (PFA; Sigma-Aldrich) and permeabilized with 0.1 % TX-100 in TBS. The cells were blocked for 30 min at room temperature with 5 % BSA; incubated with primary antibodies against NF-H(SMI-32) (mouse monoclonal antihuman; Abcam, USA, 1:200), beta-tubulin III (mouse monoclonal antihuman; Abcam, 1:200), choline acetyltransferase (Chat) (mouse monoclonal antihuman; Abcam, 1:200), and Islet-1 (mouse monoclonal antihuman; Abcam, 1:200); and diluted in 5 % BSA in PBS overnight. Secondary antibodies included Alexa fluor 488 donkey anti-mouse (1:500; Gibco, A-11058) or Alexa Fluor 594 donkey anti-rabbit (1:700; Gibco, A-21207), and the nuclei were counterstained with DAPI (Sigma-Aldrich, D8417). For negative controls, only the secondary antibodies were used. To quantify the number of positive cells for each antibody, at least ten microscopic fields per well were counted randomly and reported in relative to whole DAPI-stained nuclei as percentage.

## Molecular Analysis Using Real-Time-PCR

Quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) was used for the mRNA expression patterns of neuronal markers in treatment groups. Total RNA was extracted by using RNeasy Plus Mini kit (Qiagen, USA, 74134), and complementary DNA (cDNA) synthesis from 1 µg of RNA was performed by Revert Aid First Strand cDNA Synthesis kit (Takara, USA, K1632). qRT-PCR reactions were carried out in the 48-well optical reaction plates on StepOne™ Real-Time PCR machine. In each PCR reaction, 30 ng synthesized cDNA was used to PCR by mixing with 10 µl of Power SYBER Green master mix (2×, Applied Biosystems), 0.5 µM of each primer (Table 1) in a total volume of 20 µl at the annealing temperature. The comparative Ct method, 2<sup>-DDCt</sup>, was used for relative gene expression analysis.

## Statistical Analysis

The data were presented as means ± standard deviation of the means ( $n = 3$ ). Statistical analysis was carried out using one-way ANOVA, and difference between groups was considered statistically significant if  $P > 0.05$ .

## Results

### Isolation and Identification of Human MSCs Derived from Wharton's Jelly

Flow cytometry analysis which was published in our previous report (17) showed that CD90+ (93.6), CD105+ (90.7), and

**Table 1** Primers used for real-time RT-PCR

Gene	Primer sequence(5'–3')	Annealing (°C)
Nestin	F AAAGTTCCAGCTGGCTGTGG	55
	R TCCAGCTTGGGGTCCTGAAA	
Pax-6	F CGGTTTCTCCTTCACAT	50
	R ATCATAACTCCGCCCAT	
Islet 1	F ATATCAGGTTGTACGGGTCAAAT	56
	R CACGCATCACGAAGTCGTTT	
Chat	F GCAGGAGAAGACAGCCAACT	55
	R AAACCTCAGCTGGTCAT	
NF-H	F CAGAGCTGGAGGCACTGAAA	55
	R CTGCTGAATGGCTTCCTGGT	
Hb9	F AGCACCAGTTCAAGCTCAACA	55
	R ACCAAATCTTACCTGGGTCTC	
GAPDH	F TCGCCAGCCGAGCCA	55
	R CCTTGACGGTGCCATGGAAT	

CD73+ (89.8) were highly expressed in hWJ-MSCs and cells were negative for CD34 and CD4 (hematopoietic lineage markers).

### Fabrication of PCL Electrospun Nanofibrous Scaffolds

PCL nanofibers fabricated by electrospinning technique were used in this study. Electrospinning of PCL nanofibers was homogeneous without any bead and branching. Scanning electron microscopy micrographs showed that the average diameter of fibers was 100 nm as shown in Fig. 1a, b. The morphology and the interaction between cells and PCL electrospun scaffold were scanned at 3 days after cell seeding. Images demonstrated that cells attached, grew, and spread on the PCL nanofibrous scaffolds (Fig. 1a, b).

### Assessment of Cell Adhesion and Viability

MTT assay was performed to investigate the viability of cells cultured on PCL scaffolds as 3D group and TCP as 2D culture, at 1, 3, 5, and 7 days. As shown in Fig. 1c, until day 3, the WJ-MSCs cultured on TCP and PCL scaffold showed higher viability than cells cultured on the PCL scaffold but was not statistically significant. However, in days 5 and 7, the viability of WJ-MSCs cultured on PCL scaffold significantly enhanced relative to cells cultured on 2D control group (Fig. 2). The results obtained from MTT assay showed that PCL nanofibrous scaffolds were suitable substrates than TCPs in relation to cell attachment and proliferation.

### Evaluation of WJ-MSC Differentiation into Motor Neuron-Like Cell by PMA

To confirm motor neuron-like cell differentiation, expression of neural markers including NF-H, Chat, and Islet-1 was


investigated by immunofluorescence staining at day 15. Figure 3 shows that the random field counting of immunofluorescence images shows the percentage. Our results showed a higher expression of NF-H, choline acetyltransferase (Chat), and Islet-1 in two groups. Neuronal cell marker expression in TCP group was compared with PCL group. The expression of NF-H (50 %), Chat (78 %), and Islet-1 (82 %) in the PCL group was higher than the expression of NF-H (42 %), Chat (61 %), and Islet-1 (76 %) in the TCP group, but the expression of Chat in the PCL group in comparison with the TCP group was statistically significant (Fig. 3). The mRNA expression of neural specific genes was observed during WJ-MSC differentiation by qRT-PCR at day 15 of induction for TCP and PCL scaffold groups. The expression of nestin, Pax6, Islet-1, Chat, NF-H, and HB9 mRNAs was compared in TCP and PCL groups vs undifferentiated WJ-MSCs as a control group. According to our results, while the expression of Islet-1, Chat, NF-H, and HB9 increased significantly during differentiation, the expression of nestin and Pax6 was down-regulated following induction. The comparison results between TCP and PCL groups showed that in the PCL group, the expression of Islet-1 ( $P > 0.01$ ), Chat ( $P > 0.05$ ), NF-H ( $P > 0.05$ ), and HB9 ( $P > 0.01$ ) was higher than in the PCL group and was statistically significant as shown in Fig. 4. These results confirmed that treatment with PMA could induce differentiation of WJ-MSCs into motor neuron-like cells and PCL nanofibrous provides a suitable condition to cell differentiation.

### Discussion

The main goal of this study was to indicate the capability of cultured WJ-MSCs on PCL nanofibrous scaffold to differentiate into motor neuron-like cells in the presence of PMA as a small molecule that mimics Shh protein. In this study, we found that stimulation of hedgehog signaling pathway by means of PMA leads to promotion of WJ-MSC differentiation to motor neuron-like cells. Expression of specific markers such as beta-tubulin III, Chat, Islet-1, NF-H, HB9, Pax6, and nestin in protein and mRNA levels was analyzed using real-time PCR and immunocytochemistry, respectively.

The results of immunocytochemistry and real-time PCR represented the higher amount of differentiation to motor neuron-like cells in cultured cells on PCL scaffold relative to those on a TPC surface (2D control group).

It has been demonstrated that biomaterials are designed to create a niche that provides the appropriate microenvironment to enhance cell survival [29–32]. In line with previous studies, our MTT assay results showed that the viability of WJ-MSCs cultured on PCL scaffold highly increased relative to cells cultured on TPC surface.



**Fig. 1** Scaffold characterization analysis. **a** Scanning electron micrographs showing PCL scaffolds with and without cells. The fibers of PCL scaffold were randomly entangled to form a flexible and porous 3D matrix (scale bar 20 and 5 μm). Plated cells on PCL scaffold that grew on PCL scaffold 5 days after seeding (scale bar 20 μm). **b**


Histogram shows diameters of the PCL nanofibers. The average of fiber diameter and diameter distribution of the fibers was measured by analyzing SEM micrographs by measuring 50 fibers per condition using the ImageJ software


Importantly, for those kinds of neurological disorders [33–35] that motor neurons are affected [36], the generated neurons may need to contain a large population of motor neurons that can enhance therapeutic efficacy [37]. Thus, signaling pathways that induce differentiation of motor neurons, such as Shh, can potentially improve the efficiency of cell transplants, as overall, fewer cells need to be injected because of a higher motor neuronal yield [38, 39].

Shh is known to promote MSC differentiation into motor neuron-like cells [10, 17]. The previous studies have demonstrated that Shh signaling pathway plays a critical role in development and generation of motor neuron in embryo [40].

Enhancing of neuronal differentiation can be obtained by using chemical factors that stimulate signaling pathways controlling the development of neurons [41]. Moreover, these factors present an opportunity to provide more control over

**Fig. 2** MTT assay. Formosan absorbance expressed as a measure of cell viability from the cell cultured on TCP (2D) and PCL (3D) nanofibrous scaffolds for 7 days





**Fig. 3** Immunofluorescence staining of differentiated cells on TCP and PCL scaffolds after 15 days post induction for motor neuron markers including Chat, Islet-1, and NF-H. Scale bar 50 μm. Expression (ratio


of positive cells, %) of motor neuron markers after 15 days induction. Data are expressed as mean ± SD; three wells (ten fields per well) in each group. \**P* < 0.05 vs TCP group and PCL group

the neuronal fate of transplanted cells [42]. PMA, a synthetic small molecule, may also improve neuronal differentiation [21, 43] through activation of the smoothed receptor, which directly acts on the same signaling pathway as Shh [44]. One great advantage of small synthetic molecules, such as PMA, compared with naturally occurring molecules, such as Shh, is their stability [45]. PMA acts on the SMO receptor, binding of PMA to this receptor lead to increase of Gli1 expression, which is downstream of the Hedgehog pathway [43, 46]. Moreover, it has been demonstrated that Gli1 also has a neuroprotective effect on dopaminergic neurons in experimental

models of neurodegenerative diseases [47]. Additionally, there is also a growing body of evidence about the activation of pro-survival signaling pathways such as autophagy under control of Shh pathway [47, 48]. Autophagy pathway plays a critical role in maintenance of neural precursor cells [49]. Thus, activation of Shh pathway by means of PMA may lead to an increase of cellular viability during differentiation of WJ-MSCs into motor neuron-like cells.

Indeed, action of PMA on the Hedgehog pathway through SMO is necessary to induce neuronal differentiation [50, 51]. Furthermore, it has shown that PMA not only increased

**Fig. 4** Quantitative mRNA expression analysis of motor neuron-like cells derived from WJ-MSCs seeded on PCL scaffold after 15 days. The result of mRNA expression on TCP and PCL compared to undifferentiated WJ-MSCs. \**P* > 0.05, \*\**P* > 0.01 vs control (*n* = 3 biological samples, mean ± SEM)



neuronal differentiation but also increased the speed of differentiation [37]. In accordance with previous achievements, our results showed that PMA dramatically promotes differentiation of WJ-MSCs into motor neuron-like cells.

## Conclusion

In conclusion, the results of this study appear that PMA can be used for MSC differentiation towards a motor neuron phenotype. Expression of motor neuron markers such as Chat, Islet-1, and NF-H in RNA and protein levels by real-time PCR and immunocytochemistry showed that PMA, a synthetic small molecule, promotes differentiation of WJ-MSCs into motor neuron-like cells cultured on PCL scaffold. Therefore, our achievements lead to a novel strategy for motor neuron derivation from WJ-MSCs in vitro and hence would provide an enabling tool for stem cell-based therapy of neurological disorders in the future.

**Acknowledgments** We thank the Tehran University of Medical Sciences for the financial support (grant number 26229) and Craniomaxillofacial Research Center.

## References

- Mothe AJ, Tator CH (2013) Review of transplantation of neural stem/progenitor cells for spinal cord injury. *Int J Dev Neurosci* 31(7):701–713
- Parr AM, Kulbatski I, Zahir T, Wang X, Yue C, Keating A, Tator CH (2008) Transplanted adult spinal cord-derived neural stem/progenitor cells promote early functional recovery after rat spinal cord injury. *Neurosci* 155(3):760–770
- Yuan YM, He C (2013) The glial scar in spinal cord injury and repair. *Neurosci Bull* 29(4):421–435
- Rolls A, Shechter R, Schwartz M (2009) The bright side of the glial scar in CNS repair. *Nat Rev Neurosci* 10(3):235–241
- Krabbe C, Zimmer J, Meyer M (2005) Neural transdifferentiation of mesenchymal stem cells—a critical review. *APMIS* 113:831–844
- Lei Z, Yongda L, Jun M, Yingyu S, Shaoju Z, Xinwen Z, Mingxue Z (2007) Culture and neural differentiation of rat bone marrow mesenchymal stem cells in vitro. *Cell Biol Int* 31:916–923
- Hoveizi E, Tavakol S, Ebrahimi-Barough S (2014) Neuroprotective effect of transplanted neural precursors embedded on PLA/CS scaffold in an animal model of multiple sclerosis. *Mol Neurobiol* 51(3):1334–1342
- Ebrahimi-Barough S, Norouzi Javidan A, Saberi H, Joghataei MT, Rahbarghazi R, Mirzaei E, Faghihi F, Shirian S, et al. (2014) Evaluation of motor neuron-like cell differentiation of hEnSCs on biodegradable PLGA nanofiber scaffolds. *Mol Neurobiol* 52(3):1704–1713
- Ebrahimi-Barough S, Kouchesfahani HM, Ai J, Massumi M (2013) Differentiation of human endometrial stromal cells into oligodendrocyte progenitor cells (OPCs). *J Mol Neurosci* 51:265–273
- Ebrahimi-Barough S, Hoveizi E, Yazdankhah M, Ai J, Khakbiz M, Faghihi F, Tajerian R, Bayat N (2016) Inhibitor of PI3K/Akt signaling pathway small molecule promotes motor neuron differentiation of human endometrial stem cells cultured on electrospun biocomposite polycaprolactone/collagen scaffolds. *Mol Neurobiol*
- Ebrahimi-Barough S, Hoveizi E, Norouzi Javidan A, Ai J (2015) Investigating the neuroglial differentiation effect of neuroblastoma conditioned medium in human endometrial stem cells cultured on 3D nanofibrous scaffold. *J Biomed Mater Res A* 103(8):2621–2627
- Asmani MN, Ai J, Amoabediny G, Noroozi A, Azami M, Ebrahimi-Barough S, Navaei-Nigjeh M, Ai A, et al. (2013) Three-dimensional culture of differentiated endometrial stromal cells to oligodendrocyte progenitor cells (OPCs) in fibrin hydrogel. *Cell Biol Int* 37:1340–1349
- Navaei-Nigjeh M, Amoabediny G, Noroozi A, Azami M, Asmani MN, Ebrahimi-Barough S, Saberi H, Ai A, et al. (2014) Enhancing neuronal growth from human endometrial stem cells derived neuron-like cells in three-dimensional fibrin gel for nerve tissue engineering. *J Biomed Mater Res Part A* 102(8):2533–2543
- Zhou C, Yang B, Tian Y, Jiao H, Zheng W, Wang J, Guan F (2011) Immunomodulatory effect of human umbilical cord Wharton's jelly-derived mesenchymal stem cells on lymphocytes. *Cell Immunol* 272(1):33–38
- Fu YS, Cheng YC, Lin MY, Cheng H, Chu PM, Chou SC, Shih YH, Ko MH, et al. (2006) Conversion of human umbilical cord mesenchymal stem cells in Wharton's jelly to dopaminergic neurons in vitro: potential therapeutic application for parkinsonism. *Stem Cells* 24(1):115–124
- Bagher Z, Azami M, Ebrahimi-Barough S, Mirzadeh H, Solouk A, Soleimani M, Ai J, Nourani MR, et al. (2016) Differentiation of Wharton's jelly-derived mesenchymal stem cells into motor neuron-like cells on three-dimensional collagen-grafted nanofibers. *Mol Neurobiol* 53(4):2397–2408
- Bagher Z, Ebrahimi-Barough S, Azami M, Mirzadeh H, Soleimani M, Ai J, Nourani MR, Joghataei MT (2015) Induction of human umbilical Wharton's jelly-derived mesenchymal stem cells toward motor neuron-like cells. *In Vitro Cell Dev Biol Anim* 51(9):987–994
- Bagher Z, Ebrahimi-Barough S, Azami M, Safa M, Joghataei MT (2015) Cellular activity of Wharton's jelly-derived mesenchymal stem cells on electrospun fibrous and solvent-cast film scaffolds. *J Biomed Mater Res A* 104(1):218–226
- Cui X, Chen L, Xue T, Yu J, Liu J, Ji Y, Cheng L (2015) Human umbilical cord and dental pulp-derived mesenchymal stem cells: biological characteristics and potential roles in vitro and in vivo. *Mol Med Rep* 11(5):3269–3278
- Xiao YZ, Wang S (2015) Differentiation of Schwann-like cells from human umbilical cord blood mesenchymal stem cells in vitro. *Mol Med Rep* 11(2):1146–1152
- Wu X, Walker J, Zhang J, Ding S, Schultz PG (2004) Purmorphamine induces osteogenesis by activation of the hedgehog signaling pathway. *Chem Biol* 11(9):1229–1238
- Faghihi F, Baghaban Eslaminejad M, Nekookar A, Najar M, Salekdeh GH (2013) The effect of purmorphamine and sirolimus on osteogenic differentiation of human bone marrow-derived mesenchymal stem cells. *Biomed Pharmacother* 67(1):31–38
- Zhang P, Xia N, Reijo Pera RA (2014) Directed dopaminergic neuron differentiation from human pluripotent stem cells. *J Vis Exp* 91:51737
- Binan L, Tendey C, De Crescenzo G, El Ayoubi R, Ajji A, Jolicœur M (2014) Differentiation of neuronal stem cells into motor neurons using electrospun poly-L-lactic acid/gelatin scaffold. *Biomaterials* 35(2):664–674
- Rapacioli M, Botelho J, Cerda G, Duarte S, Elliot M, Palma V, Flores V (2012) Sonic hedgehog (Shh)/Gli modulates the spatial organization of neuroepithelial cell proliferation in the developing chick optic tectum. *BMC Neurosci* 13:117
- Spring DR (2011) Chemical genetics to chemical genomics: small molecules offer big insights. *Chem Soc Rev* 34:472–482

27. Rim NG, Shin CS, Shin H (2013) Current approaches to electrospun nanofibers for tissue engineering. *Biomed Mater* 8: 014102
28. Ghasemi-Mobarakeh L, Morshed M, Karbalaie K, Fesharaki MA, Nematollahi M, Nasr-Esfahani MH, Baharv H (2009) The thickness of electrospun poly (epsilon-caprolactone) nanofibrous scaffolds influences cell proliferation. *Int J Artif Organs* 32:150–158
29. Shrestha B, Coykendall K, Li Y, Moon A, Priyadarshani P, Yao L (2014) Repair of injured spinal cord using biomaterial scaffolds and stem cells. *Stem Cell Res Ther* 5(4):91
30. Shirian, ES, Ebrahimi-Barough S, Saberi H, Norouzi-Javidan A, Mousavi, SM, Derakhshan, MA, Arjmand B, Ai, J (2016) Comparison of capability of human bone marrow mesenchymal stem cells and endometrial stem cells to differentiate into motor neurons on electrospun poly( $\epsilon$ -caprolactone) scaffold. *Mol Neurobiol*
31. Bayat N, Ebrahimi-Barough S, Ardakan MM, Ai A, Kamyab A, Babaloo N, Ai J (2015) Differentiation of human endometrial stem cells into Schwann cells in fibrin hydrogel as 3D culture. *Mol Neurobiol*
32. Mirzaei E, Ai J, Ebrahimi-Barough S, Verdi J, Ghanbari H, Faridi-Majidi R (2015) The differentiation of human endometrial stem cells into neuron-like cells on electrospun PAN-derived carbon nanofibers with random and aligned topographies. *Mol Neurobiol*
33. Harirchian MH, Tekieh AH, Modabbernia A, Aghamollaii V, Tafakhori A, Ghaffarpour M, Sahraian MA, Najji M, et al. (2012) Serum and CSF PDGF-AA and FGF-2 in relapsing-remitting multiple sclerosis: a case-control study. *Eur J Neurol* 19(2):241–247
34. Masoudian N, Riazi GH, Afrasiabi A, Modaresi SM, Dadras A, Rafiei S, Yazdankhah M, Lyaghi A, et al. (2015) Variations of glutamate concentration within synaptic cleft in the presence of electromagnetic fields: an artificial neural networks study. *Neurochem Res* 40(4):629–642
35. Mashayekhi F, Azari M, Moghadam LM, Yazdankhah M, Najji M, Salehi Z (2009) Changes in cerebrospinal fluid nerve growth factor levels during chick embryonic development. *J Clin Neurosci* 16(10):1334–1337
36. Schmitt F, Hussain G, Dupuis L, Loeffler JP, Henriques A (2014) A plural role for lipids in motor neuron diseases: energy, signaling and structure. *Front Cell Neurosci* 8:25
37. El-Akabawy G, Medina LM, Jeffries A, Price J, Modo M (2011) Purmorphamine increases DARPP-32 differentiation in human striatal neural stem cells through the Hedgehog pathway. *Stem Cell Dev* 20(11):1873–1887
38. Fernandez-Santiago R, Ezquerro M (2016) Epigenetic research of neurodegenerative disorders using patient iPSC-based models. *Stem Cells Int* 2016:9464591
39. Castorina A, Szychlińska MA, Marzagalli R, Musumeci G (2015) Mesenchymal stem cells-based therapy as a potential treatment in neurodegenerative disorders: is the escape from senescence an answer? *Neural Regen Res* 10(6):850–858
40. Oh S, Huang X, Liu J, Litingtung Y, Chiang C (2009) Shh and Gli3 activities are required for timely generation of motor neuron progenitors. *Dev Biol* 331(2):261–269
41. Greco SJ, Rameshwar P (2010) Recent advances and novel approaches in deriving neurons from stem cells. *Mol BioSys* 6(2): 324–328
42. Boehler RM, Graham JG, Shea LD (2011) Tissue engineering tools for modulation of the immune response. *BioTechniques* 51(4):239–240 242, 244 passim
43. Sinha S, Chen JK (2006) Purmorphamine activates the Hedgehog pathway by targeting Smoothened. *Nature Chem Biol* 2(1):29–30
44. Li XJ, Hu BY, Jones SA, Zhang YS, Lavaute T, Du ZW, Zhang SC (2008) Directed differentiation of ventral spinal progenitors and motor neurons from human embryonic stem cells by small molecules. *Stem Cells* 26(4):886–893
45. Stanton BZ, Peng LF (2010) Small-molecule modulators of the sonic hedgehog signaling pathway. *Mol Bio Sys* 6(1):44–54
46. Riobo NA, Saucy B, Dilizio C, Manning DR (2006) Activation of heterotrimeric G proteins by Smoothened. *Proc Natl Acad Sci U S A* 103(33):12607–12612
47. Hurtado-Lorenzo A, Millan E, Gonzalez-Nicolini V, Suwelack D, Castro MG, Lowenstein PR (2004) Differentiation and transcription factor gene therapy in experimental Parkinson's disease: sonic hedgehog and Gli-1, but not Nurr-1, protect nigrostriatal cell bodies from 6-OHDA-induced neurodegeneration. *Mol Ther* 10(3):507–524
48. Petralia RS, Schwartz CM, Wang YX, Kawamoto EM, Mattson MP, Yao PJ (2013) Sonic hedgehog promotes autophagy in hippocampal neurons. *Biology open* 2(5):499–504
49. Wu X, Won H, Rubinsztein DC (2013) Autophagy and mammalian development. *Biochem Soc Trans* 41(6):1489–1494
50. Yazdankhah M, Farioli-Vecchioli S, Tonchev AB, Stoykova A, Cecconi F (2014) The autophagy regulators Ambra1 and Beclin 1 are required for adult neurogenesis in the brain subventricular zone. *Cell Death Dis* 5:e1403
51. Nat R, Salti A, Suci L, Strom S, Dechant G (2012) Pharmacological modulation of the Hedgehog pathway differentially affects dorsal/ventral patterning in mouse and human embryonic stem cell models of telencephalic development. *Stem Cell Dev* 21(7):1016–1046



## Terms and Conditions

Springer Nature journal content, brought to you courtesy of Springer Nature Customer Service Center GmbH (“Springer Nature”).

Springer Nature supports a reasonable amount of sharing of research papers by authors, subscribers and authorised users (“Users”), for small-scale personal, non-commercial use provided that all copyright, trade and service marks and other proprietary notices are maintained. By accessing, sharing, receiving or otherwise using the Springer Nature journal content you agree to these terms of use (“Terms”). For these purposes, Springer Nature considers academic use (by researchers and students) to be non-commercial.

These Terms are supplementary and will apply in addition to any applicable website terms and conditions, a relevant site licence or a personal subscription. These Terms will prevail over any conflict or ambiguity with regards to the relevant terms, a site licence or a personal subscription (to the extent of the conflict or ambiguity only). For Creative Commons-licensed articles, the terms of the Creative Commons license used will apply.

We collect and use personal data to provide access to the Springer Nature journal content. We may also use these personal data internally within ResearchGate and Springer Nature and as agreed share it, in an anonymised way, for purposes of tracking, analysis and reporting. We will not otherwise disclose your personal data outside the ResearchGate or the Springer Nature group of companies unless we have your permission as detailed in the Privacy Policy.

While Users may use the Springer Nature journal content for small scale, personal non-commercial use, it is important to note that Users may not:

1. use such content for the purpose of providing other users with access on a regular or large scale basis or as a means to circumvent access control;
2. use such content where to do so would be considered a criminal or statutory offence in any jurisdiction, or gives rise to civil liability, or is otherwise unlawful;
3. falsely or misleadingly imply or suggest endorsement, approval, sponsorship, or association unless explicitly agreed to by Springer Nature in writing;
4. use bots or other automated methods to access the content or redirect messages
5. override any security feature or exclusionary protocol; or
6. share the content in order to create substitute for Springer Nature products or services or a systematic database of Springer Nature journal content.

In line with the restriction against commercial use, Springer Nature does not permit the creation of a product or service that creates revenue, royalties, rent or income from our content or its inclusion as part of a paid for service or for other commercial gain. Springer Nature journal content cannot be used for inter-library loans and librarians may not upload Springer Nature journal content on a large scale into their, or any other, institutional repository.

These terms of use are reviewed regularly and may be amended at any time. Springer Nature is not obligated to publish any information or content on this website and may remove it or features or functionality at our sole discretion, at any time with or without notice. Springer Nature may revoke this licence to you at any time and remove access to any copies of the Springer Nature journal content which have been saved.

To the fullest extent permitted by law, Springer Nature makes no warranties, representations or guarantees to Users, either express or implied with respect to the Springer nature journal content and all parties disclaim and waive any implied warranties or warranties imposed by law, including merchantability or fitness for any particular purpose.

Please note that these rights do not automatically extend to content, data or other material published by Springer Nature that may be licensed from third parties.

If you would like to use or distribute our Springer Nature journal content to a wider audience or on a regular basis or in any other manner not expressly permitted by these Terms, please contact Springer Nature at

[onlineservice@springernature.com](mailto:onlineservice@springernature.com)